Takeda Bio Development Center Limited.

What's New

May 11, 2012 Update on Product Pipeline
April 1, 2012 Update on Message from Top Management
February 1, 2012 Update on Overview
January 27, 2012 Anti-Prostate Cancer Agent Orteronel(TAK-700) Enters into Phase III Clinical Trials in Japan
October 11, 2011 Brentuximab Vedotin Enters Phase 1/2 Clinical Trial in Japan
August 11, 2011 Update on Careers

January 27, 2012 Anti-Prostate Cancer Agent Orteronel(TAK-700) Enters into Phase III Clinical Trials in Japan
October 11, 2011 Brentuximab Vedotin Enters Phase 1/2 Clinical Trial in Japan
April 14, 2011 Anti-Cancer Agent AMG 479 Enters into the Phase III Clinical Trial in Japan
March 30, 2011 TOP-LINE RESULTS ANNOUNCED OF PIVOTAL PHASE 3 MOTESANIB TRIAL IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
January 24, 2011 Anti-Cancer Agent AMG 386 Enters into Phase III Clinical Trials in Japan
June 15, 2010 Launch of Anti-Cancer Agent “Vectibix®” in Japan (Takeda Pharmaceutical Company Limited)
April 16, 2010 New Drug Applications Approval for Anti-Cancer Agent, Panitumumab (Recombinant) (Takeda Pharmaceutical Company Limited)